Trial Profile

A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Batoclimab (Primary)
Indications Chronic inflammatory demyelinating polyradiculoneuropathy
Focus Registrational; Therapeutic Use
Sponsors Immunovant

Most Recent Events

19 Mar 2025 Results presented in the Immunovant Media Release.
19 Mar 2025 Results (n=73) consisting pooled data from period 1 presented in the Roivant sciences Media Release.
18 Mar 2025 According to a Roivant sciences media release, company announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review initial results from its Phase 2b study in CIDP.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com